vTv Therapeutics Inc.

NasdaqCM:VTVT Stock Report

Market Cap: US$428.6m

vTv Therapeutics Future Growth

Future criteria checks 0/6

vTv Therapeutics's revenue and earnings are forecast to decline at 1.5% and 24.9% per annum respectively while EPS is expected to decline by 19.9% per annum.

Key information

-24.9%

Earnings growth rate

-19.86%

EPS growth rate

Biotechs earnings growth25.1%
Revenue growth rate-1.5%
Future return on equityn/a
Analyst coverage

Good

Last updated15 May 2026

Recent future growth updates

Recent updates

Analysis Article • Apr 06

We Think vTv Therapeutics (NASDAQ:VTVT) Can Easily Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. Indeed, vTv Therapeutics ( NASDAQ:VTVT...
Analysis Article • Dec 02

Here's Why We're Not Too Worried About vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 11

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Feb 02

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 24

Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • May 11

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, vTv Therapeutics...
Seeking Alpha • Aug 16

vTv Therapeutics GAAP EPS of -$0.04

vTv Therapeutics press release (NASDAQ:VTVT): Q2 GAAP EPS of -$0.04.  The Company’s cash position as of June 30, 2022, was $17.9M compared to $13.4M as of December 31, 2021.
Seeking Alpha • Jul 25

vTv stock soars 18% on $10M equity investment by CinRx Pharma

vTv Therapeutics (NASDAQ:VTVT) is raising $10M via an equity investment by CinPax, a unit of CinRx Pharma. Under the agreements, CinPax acquired ~4.15M class A Common shares of vTv at ~$2.41 apiece. About $6M will be paid in cash at closing, and the remaining $4M payable on Nov. 22. vTv will also issue 1.2M warrants to to CinRx to acquire additional class A shares which become exercisable upon agreed vesting triggers (including FDA approval of TTP399. vTv said it will use CinRx's industry experience to collaborate on the oversight of clinical trials for pharmaceutical products that contain TTP399. VTVT +18.70% to $0.85 premarket July 25
Analysis Article • Aug 17

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqCM:VTVT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-69-58-635
12/31/2027N/A-59-53-666
12/31/202622-23-23-466
3/31/2026372-10-10N/A
12/31/2025N/A-27-25-25N/A
9/30/20250-23-21-21N/A
6/30/20250-20-22-22N/A
3/31/20250-19-24-24N/A
12/31/20241-18-25-25N/A
9/30/20241-18-23-23N/A
6/30/20241-20-22-22N/A
3/31/20241-21-21-21N/A
12/31/2023N/A-20-19-19N/A
9/30/20230-22-23-23N/A
6/30/20230-19-27-27N/A
3/31/20230-17-20-20N/A
12/31/20222-19-16-16N/A
9/30/20222-21-16-16N/A
6/30/20225-18-10-10N/A
3/31/20225-16-15-15N/A
12/31/20214-13-19-19N/A
9/30/202110-5-15-15N/A
6/30/20217-5-17-17N/A
3/31/20217-8-18-18N/A
12/31/20206-8-18-18N/A
9/30/20200-15-22-22N/A
6/30/20200-17-22-22N/A
3/31/20202-17-23-23N/A
12/31/20193-18N/A-23N/A
9/30/20197-15N/A-23N/A
6/30/201911-11N/A-23N/A
3/31/201911-12N/A-27N/A
12/31/201812-9N/A-27N/A
9/30/20188-11N/A-27N/A
6/30/20185-14N/A-33N/A
3/31/20182-15N/A-36N/A
12/31/20170-16N/A-45N/A
9/30/20170-16N/A-50N/A
6/30/20170-16N/A-51N/A
3/31/20170-17N/A-50N/A
12/31/20161-16N/A-48N/A
9/30/20161-15N/A-46N/A
6/30/20161-16N/A-43N/A
3/31/20161-22N/A-40N/A
12/31/20151-27N/A-37N/A
9/30/20151-32N/A-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VTVT's earnings are forecast to decline over the next 3 years (-24.9% per year).

Earnings vs Market: VTVT's earnings are forecast to decline over the next 3 years (-24.9% per year).

High Growth Earnings: VTVT's earnings are forecast to decline over the next 3 years.

Revenue vs Market: VTVT's revenue is expected to decline over the next 3 years (-1.5% per year).

High Growth Revenue: VTVT's revenue is forecast to decline over the next 3 years (-1.5% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if VTVT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 22:06
End of Day Share Price 2026/07/07 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

vTv Therapeutics Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Douglas BuchananBrean Capital Historical (Janney Montgomery)
Kambiz YazdiBTIG